

Dizziness

Non-steroidal anti-inflammatory drug

First author, year of publication	NSAID	Regimen	Endpoints	EER	CER	active	control	endpoint with active	endpoint with control
[Balestrieri, 1997]	ketorolac	60 mg + 30 mg/6h iv	Dizziness	8.4%	3.7%	166	82	14	3
[Hsu, 2003]	tenoxicam	20 mg iv	Dizziness	28.9%	29.2%	45	48	13	14
[Perttunen, 1992]	diclofenac	2 mg/kg /h (48h) iv	Dizziness	40.0%	26.7%	15	15	6	4
[Ready, 1994]	ketorolac	30 mg + 5 mg /h iv	Dizziness	8.8%	18.3%	136	71	12	13
[Varrassi, 1994]	ketorolac	30 mg im+ 2 mg /h iv	Dizziness	0.0%	4.3%	48	47	0	2
[Vandermeulen, 1997]	tenoxicam	40 mg iv	Dizziness/ confusion	1.6%	2.3%	258	256	4	6

Selective cyclo-oxygenase 2 inhibitor

First author, year of publication	Cox-2	Regimen	Endpoints	EER	CER	active	control	endpoint with active	endpoint with control
[Malan, 2003]	parecoxib	20-40 mg /12h iv	Dizziness	3.8%	5.7%	131	70	5	4
[Ott, 2003]	parecoxib valdecoxib	40 mg /12h iv/po	Dizziness	11.9%	17.9%	311	151	37	27
[Reynolds, 2002]	valdecoxib	20-40 mg /12h po	Dizziness	15.1%	15.7%	139	70	21	11

NSAID: non-steroidal anti-inflammatory drug; Cox-2: selective cyclo-oxygenase 2 inhibitor; EER: experimental event rate; CER: control event rate;
 iv: intravenous; im: intramuscular; po: per os